[HTML][HTML] The blood–brain barrier: structure, regulation, and drug delivery

D Wu, Q Chen, X Chen, F Han, Z Chen… - Signal Transduction and …, 2023 - nature.com
Blood–brain barrier (BBB) is a natural protective membrane that prevents central nervous
system (CNS) from toxins and pathogens in blood. However, the presence of BBB …

Fluid transport in the brain

MK Rasmussen, H Mestre… - Physiological …, 2022 - journals.physiology.org
The brain harbors a unique ability to, figuratively speaking, shift its gears. During
wakefulness, the brain is geared fully toward processing information and behaving, while …

Impaired glymphatic function and clearance of tau in an Alzheimer's disease model

IF Harrison, O Ismail, A Machhada, N Colgan, Y Ohene… - Brain, 2020 - academic.oup.com
The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with
interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid …

The glymphatic system: implications for drugs for central nervous system diseases

TJ Lohela, TO Lilius, M Nedergaard - Nature Reviews Drug Discovery, 2022 - nature.com
In the past decade, evidence for a fluid clearance pathway in the central nervous system
known as the glymphatic system has grown. According to the glymphatic system concept …

Emerging roles for dynamic aquaporin-4 subcellular relocalization in CNS water homeostasis

MM Salman, P Kitchen, A Halsey, MX Wang… - 2022 - academic.oup.com
Aquaporin channels facilitate bidirectional water flow in all cells and tissues. AQP4 is highly
expressed in astrocytes. In the CNS, it is enriched in astrocyte endfeet, at synapses, and at …

[HTML][HTML] Trial of satralizumab in neuromyelitis optica spectrum disorder

T Yamamura, I Kleiter, K Fujihara… - … England Journal of …, 2019 - Mass Medical Soc
Background Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of
the central nervous system and is associated with autoantibodies to anti–aquaporin-4 …

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

A Traboulsee, BM Greenberg, JL Bennett… - The Lancet …, 2020 - thelancet.com
Background Satralizumab, a humanised monoclonal antibody targeting the interleukin-6
receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder …

The blood-brain barrier: Physiology and strategies for drug delivery

R Pandit, L Chen, J Götz - Advanced drug delivery reviews, 2020 - Elsevier
The blood-brain barrier (BBB) is a dynamic structure that functions as a gatekeeper,
reflecting the unique requirements of the brain. In this review, following a brief historical …

[HTML][HTML] Myelin in the central nervous system: structure, function, and pathology

C Stadelmann, S Timmler… - Physiological …, 2019 - journals.physiology.org
Oligodendrocytes generate multiple layers of myelin membrane around axons of the central
nervous system to enable fast and efficient nerve conduction. Until recently, saltatory nerve …

Pathophysiology of delayed cerebral ischemia after subarachnoid hemorrhage: a review

WS Dodd, D Laurent, AS Dumont… - Journal of the …, 2021 - Am Heart Assoc
Delayed cerebral ischemia is a major predictor of poor outcomes in patients who suffer
subarachnoid hemorrhage. Treatment options are limited and often ineffective despite many …